Description
AOD-9604 5mg – Human Growth Hormone Fragment Research Peptide Australia
AOD-9604 5mg is a synthetic peptide derived from the C-terminal region of human growth hormone (hGH), listed by Peps Aussie Australia as reference material for scientific investigation, laboratory analysis and controlled experimental research.
AOD-9604 was developed to investigate whether specific biological activities associated with growth hormone could be studied independently of the full-length hormone.
The compound has attracted scientific interest in metabolic research, particularly investigations involving lipid metabolism, adipose tissue biology and growth hormone fragment pharmacology.
Published preclinical and clinical research has examined AOD-9604 in relation to fat-metabolism endpoints, metabolic signalling and the distinction between fragment activity and the broader physiological actions of human growth hormone.
However, clinical investigations have not established AOD-9604 as an approved weight-management treatment or validated fat-loss intervention.
AOD-9604 is not equivalent to full-length human growth hormone, and findings involving the intact hormone cannot automatically be attributed to the fragment.
Peps Aussie lists AOD-9604 in a nominal 5mg size for laboratory research and analytical applications.
Important: AOD-9604 is intended strictly for laboratory research and analytical purposes. It is not supplied for human or animal consumption, injection, administration, weight management, therapeutic use or clinical treatment.
What Is AOD-9604?
AOD-9604, sometimes referred to as an anti-obesity drug candidate in historical research literature, is a modified peptide fragment corresponding to the C-terminal region of human growth hormone.
It is commonly associated with amino acid residues 176–191 of human growth hormone, with structural modifications distinguishing it from the naturally occurring fragment.
Human growth hormone is a peptide hormone involved in growth, metabolism and other physiological processes.
Researchers have investigated different regions of the hormone to better understand the relationship between peptide structure and biological activity.
AOD-9604 was developed as part of this broader research into growth hormone-derived fragments.
Scientific interest has included:
- Growth hormone fragment biology.
- Lipid metabolism.
- Adipose tissue signalling.
- Experimental lipolysis pathways.
- Metabolic regulation.
- Peptide structure–activity relationships.
- Differences between fragment and full-length hormone activity.
These research topics contribute to understanding peptide pharmacology but do not establish therapeutic benefits from the Peps Aussie material.
AOD-9604 and Human Growth Hormone
Full-length human growth hormone contains 191 amino acid residues and participates in numerous physiological processes.
Its actions include direct receptor-mediated effects and indirect effects involving insulin-like growth factor 1 (IGF-1).
AOD-9604 contains only a modified portion of the hormone’s C-terminal region.
This structural distinction is important because a peptide fragment may have different receptor interactions, metabolic characteristics and biological effects from the intact hormone.
Researchers should not assume that AOD-9604 reproduces the growth-promoting, endocrine or metabolic actions of full-length hGH.
AOD-9604 Peptide Research and Scientific Applications
Published research has examined AOD-9604 across several areas of metabolic biology, peptide chemistry and experimental pharmacology.
The following sections describe scientific research topics rather than proven therapeutic effects of the Peps Aussie material.
1. Lipid Metabolism Research
One of the principal areas of AOD-9604 research involves lipid metabolism.
Lipids are important components of cellular membranes, energy storage systems and biochemical signalling pathways.
Experimental research has examined whether growth hormone-derived fragments influence aspects of lipid metabolism under controlled conditions.
Relevant topics include:
- Lipid metabolic pathways.
- Adipose tissue physiology.
- Fatty acid mobilisation.
- Experimental lipolysis.
- Lipid storage regulation.
- Metabolic signalling.
- Peptide-associated metabolic responses.
These investigations contribute to understanding the relationship between peptide structure and metabolic activity.
They do not establish that AOD-9604 produces clinically meaningful fat loss.
2. Adipose Tissue Biology
Adipose tissue is a specialised tissue involved in energy storage, endocrine signalling and metabolic regulation.
Research involving AOD-9604 has examined metabolic endpoints associated with adipose tissue.
Relevant scientific topics include:
- Adipocyte physiology.
- Lipid storage and mobilisation.
- Adipose tissue metabolic responses.
- Experimental fat metabolism.
- Cellular energy balance.
- Metabolic pathway regulation.
Findings from experimental systems must be interpreted according to the specific study conditions.
Results involving isolated cells or animal models cannot automatically be generalised to humans.
3. Growth Hormone Fragment Pharmacology
AOD-9604 was developed to investigate biological characteristics associated with a specific region of human growth hormone.
Research involving hormone-derived peptide fragments has examined how molecular structure influences biological activity.
Relevant research areas include:
- Growth hormone-derived peptide sequences.
- Fragment-specific biological activity.
- Peptide structure–activity relationships.
- Molecular modifications.
- Comparative peptide pharmacology.
- Experimental metabolic responses.
These investigations contribute to understanding how peptide fragments may differ from their parent proteins.
4. Lipolysis and Lipogenesis Research
Two important processes in lipid metabolism are lipolysis and lipogenesis.
Lipolysis refers to the breakdown of stored triglycerides into smaller components.
Lipogenesis refers to the synthesis and storage of lipids.
Preclinical AOD-9604 research has examined endpoints associated with these metabolic processes.
Relevant topics include:
- Lipolytic signalling.
- Lipid synthesis pathways.
- Fatty acid metabolism.
- Experimental metabolic regulation.
- Adipocyte-associated responses.
- Hormone-derived peptide activity.
Although these pathways are relevant to body-fat regulation, changes observed in laboratory models do not establish successful human weight management.
5. Preclinical Metabolic Research Models
AOD-9604 has been investigated in experimental models designed to evaluate metabolic activity.
Preclinical research may involve cell-based systems, animal models and biochemical measurements.
Relevant topics include:
- Experimental metabolic endpoints.
- Lipid metabolism measurements.
- Adipose tissue responses.
- Peptide-associated biochemical changes.
- Comparative metabolic pharmacology.
- Translational research limitations.
Preclinical findings are useful for generating and evaluating scientific hypotheses.
However, they do not independently establish clinical safety or efficacy.
6. Human Clinical Research and Weight-Management Endpoints
AOD-9604 has been investigated in human clinical research involving obesity-related and metabolic endpoints.
These studies are important because they allow researchers to compare experimental hypotheses with measured outcomes in human participants.
Relevant research considerations include:
- Clinical study design.
- Body-weight endpoints.
- Metabolic outcome measurements.
- Dose-response investigation.
- Statistical interpretation.
- Safety monitoring.
- Differences between preclinical and clinical findings.
Clinical development did not establish AOD-9604 as an effective, approved weight-management medicine.
The existence of human research does not demonstrate that independently supplied AOD-9604 research material is suitable for human administration.
7. AOD-9604 Compared With Full-Length Human Growth Hormone
AOD-9604 and human growth hormone are structurally related but chemically distinct.
Human Growth Hormone (hGH):
- A naturally occurring peptide hormone.
- Contains 191 amino acid residues.
- Participates in growth and metabolic regulation.
- Has established endocrine signalling pathways.
AOD-9604:
- A synthetic modified fragment of human growth hormone.
- Associated with the C-terminal region of hGH.
- Developed for investigation of metabolic signalling.
- Does not reproduce the full molecular structure of hGH.
Researchers should not treat AOD-9604 as interchangeable with human growth hormone.
8. AOD-9604 Analytical Characterisation and Quality Research
AOD-9604 is also relevant to analytical investigations involving synthetic peptide identity, molecular structure and material quality.
Laboratories evaluating AOD-9604 may investigate:
- Confirmation of peptide identity.
- Amino acid sequence verification.
- Molecular mass determination.
- Peptide structural characterisation.
- Chromatographic purity profiles.
- Peptide-related impurities.
- Quantitative content determination.
- Material stability.
- Batch-to-batch analytical consistency.
Analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry (MS) may be appropriate depending on the formulation and testing objectives.
AOD-9604 5mg Research Peptide Specifications
Peps Aussie lists AOD-9604 in a nominal 5mg size.
| Specification | Details |
|---|---|
| Product name | AOD-9604 |
| Listed size | 5mg |
| Peptide type | Synthetic modified human growth hormone fragment |
| Parent hormone | Human Growth Hormone (hGH) |
| Structural relationship | Modified C-terminal hGH fragment |
| Commonly referenced region | hGH residues 176–191 |
| Research category | Metabolic peptide research |
| Research areas | Lipid metabolism, adipose tissue biology and peptide pharmacology |
| Supplier | Peps Aussie Australia |
| Intended use | Laboratory research and analytical investigation only |
The scientific characteristics above describe AOD-9604 as discussed in published literature. They do not independently verify the identity, composition, purity or content of the supplied material.
Exact molecular identity, amino acid sequence, terminal modifications, disulfide structure where applicable, salt form, formulation, physical appearance, fill quantity and excipients should be confirmed against the applicable product label and supporting lot documentation.
AOD-9604 Certificate of Analysis (COA) and Quality Documentation
Analytical verification is an important consideration when evaluating synthetic research peptides.
Peps Aussie maintains a dedicated resource where researchers can review available Certificates of Analysis and supporting analytical records.
View Peps Aussie Certificates of Analysis
When evaluating AOD-9604 analytical documentation, researchers should consider:
- Peptide identity: Whether testing supports the declared AOD-9604 identity.
- Sequence verification: Whether analytical evidence is consistent with the expected peptide structure.
- Purity assessment: Whether suitable methods were used to evaluate impurities.
- Content determination: Whether quantitative testing supports the declared 5mg quantity.
- Batch traceability: Whether the certificate corresponds to the supplied production lot.
- Testing methodology: Whether the analytical techniques are appropriate for the peptide.
- Additional testing: Whether relevant contamination or other quality assessments were performed.
High-performance liquid chromatography and mass spectrometry are commonly used in peptide characterisation.
A certificate should be interpreted according to the tests actually performed.
The availability of a certificate does not automatically establish sterility, endotoxin status, a particular purity percentage, pharmaceutical-grade manufacturing or independent verification of every production batch.
AOD-9604 Storage and Laboratory Handling
Research peptides require appropriate handling to support sample integrity and experimental reproducibility.
Storage requirements for AOD-9604 depend on the formulation, packaging and validated manufacturer stability information.
Laboratories should consider:
- Appropriate storage temperature.
- Protection from light and moisture where necessary.
- Suitable laboratory containers.
- Compatibility with analytical solvents.
- Stability following sample preparation.
- Potential degradation during storage.
- Appropriate laboratory handling and disposal procedures.
No universal storage temperature or reconstitution procedure is recommended without verified product-specific documentation.
All laboratory work should be performed by appropriately qualified personnel using validated procedures and suitable safety controls.
AOD-9604 5mg Australia – Product Availability and Shipping
Peps Aussie maintains an Australian-based catalogue of research peptides and laboratory materials for scientific and analytical applications.
AOD-9604 5mg is the currently listed nominal product size.
Pricing and ordering availability should be confirmed through the product selection area. Inventory is currently pending confirmation.
For current information regarding Australian dispatch, delivery arrangements, processing times and applicable restrictions, visit the Peps Aussie Shipping Policy.
Frequently Asked Questions About AOD-9604
What is AOD-9604?
AOD-9604 is a synthetic modified fragment of human growth hormone, developed for investigation of metabolic signalling and lipid-metabolism endpoints.
What is AOD-9604 studied for?
Published research has examined AOD-9604 in relation to lipid metabolism, adipose tissue biology, experimental lipolysis and differences between growth hormone fragment activity and full-length growth hormone.
Is AOD-9604 the same as human growth hormone?
No. AOD-9604 is a modified fragment of human growth hormone, not the full-length hormone.
What does AOD-9604 stand for?
AOD-9604 is a research compound designation associated with its development as an anti-obesity drug candidate. The designation does not establish clinical effectiveness.
Does AOD-9604 burn fat?
AOD-9604 has been investigated in fat-metabolism research, but clinical development has not established it as an effective, approved fat-loss treatment.
Has AOD-9604 been studied in humans?
Yes. AOD-9604 has been investigated in human clinical research involving obesity-related and metabolic endpoints. These investigations do not establish clinical suitability for the Peps Aussie research material.
Is AOD-9604 a growth hormone secretagogue?
AOD-9604 is not generally classified as a growth hormone secretagogue. It is a modified fragment of human growth hormone developed for investigation of metabolic pathways.
Is AOD-9604 approved for weight loss?
No approval is claimed for AOD-9604 as a weight-management medicine. It should not be represented as a validated weight-loss intervention.
What size does Peps Aussie list?
Peps Aussie lists AOD-9604 in a 5mg nominal size. Researchers should verify the individual vial label and supporting analytical documentation.
Does AOD-9604 have a Certificate of Analysis?
Available analytical documentation can be reviewed through the Peps Aussie Certificates of Analysis page. Researchers should confirm that any applicable certificate corresponds to the specific production lot and evaluate the tests performed.
How should AOD-9604 be stored?
Storage requirements depend on the formulation and validated stability characteristics. Follow the manufacturer’s product-specific documentation and established laboratory procedures.
Is AOD-9604 approved for human or veterinary use?
No medical or veterinary approval is claimed for the Peps Aussie AOD-9604 research product.
This product is not supplied for human or animal consumption, administration, diagnosis, prevention or treatment.
AOD-9604 Research Peptides at Peps Aussie Australia
Peps Aussie maintains a catalogue of laboratory research peptides and scientific materials for researchers investigating molecular biology, metabolic signalling and peptide pharmacology.
AOD-9604 remains a subject of scientific interest because of its structural relationship with human growth hormone and its history in experimental lipid-metabolism research.
Researchers evaluating AOD-9604 5mg should prioritise accurate peptide identification, appropriate analytical documentation, batch traceability and validated laboratory procedures.
Explore the Peps Aussie research catalogue at pepsaussie.com.
Research Use Only Disclaimer
AOD-9604 5mg is intended strictly for laboratory research and analytical purposes only.
This product is not intended for human or animal consumption, injection, administration, weight management, therapeutic use or clinical treatment.
Descriptions of published scientific research are provided for educational and informational purposes only. They do not establish fat-loss benefits, improved metabolism, clinical safety or therapeutic suitability for the material offered.
AOD-9604 is not established as an approved weight-management treatment.
No dosing, self-administration or therapeutic guidance is provided.

Reviews
There are no reviews yet.